Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases (Q36671522)

15 August 2017

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases (English)

1 reference

15 August 2017

phase II clinical trial

0 references

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6601320

26 March 2024

3

J. Bauer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

Thomas Kurt Eigentler

6

object named as

T. K. Eigentler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

9

C. Garbe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

author name string

P. Radny

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

U. M. Caroli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

T. Paul

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

C. Schlegel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

B. Weide

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

M. Schwarz

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

26 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

PMCID

2394422

15 August 2017

3 November 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14583759

full work available at URL

26 March 2024

https://www.nature.com/articles/6601320.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

https://europepmc.org/articles/PMC2394422

26 March 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

https://europepmc.org/articles/PMC2394422?pdf=render

26 March 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14583759

http://www.nature.com/articles/6601320.pdf

26 March 2024

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1038/SJ.BJC.6601320

http://www.nature.com/articles/6601320

26 March 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1038/SJ.BJC.6601320

British Journal of Cancer

26 March 2024

published in

1 reference

15 August 2017

89

1 reference

15 August 2017

9

1 reference

15 August 2017

1620-1626

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601320

15 August 2017

0 references

cites work

Advances in specific immunotherapy of malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Melanoma. A multidisciplinary approach for the general surgeon

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Therapeutic advances in melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Bleomycin-mediated electrochemotherapy of metastatic melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394422

Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor

20 September 2018

1 reference

12 December 2020

Intralesional interferon treatment of lentigo maligna

1 reference

12 December 2020

A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy

1 reference

12 December 2020

Regressive effect of intralesional injection of a moderate dose of recombinant interleukin-2 on carcinoma erysipeloides from gastric carcinoma

1 reference

12 December 2020

Intralesional interferon-alpha therapy in advanced malignant melanoma

1 reference

12 December 2020

Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine

1 reference

12 December 2020

Intralesional therapy of melanoma metastases with recombinant interferon-beta

1 reference

12 December 2020

Successful therapy of metastatic eccrine poroma using perilesional interferon alfa and interleukin 2

1 reference

12 December 2020

A case of malignant haemangioendothelioma showing response to interleukin 2 therapy

1 reference

12 December 2020

Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma

1 reference

12 December 2020

[Peritumoral administered IL-2-induced tumor regression in melanoma. Pilot study]

1 reference

12 December 2020

Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study

1 reference

12 December 2020

Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV + IFN-beta therapy) into malignant melanoma

1 reference

12 December 2020

Identifiers

DOI

1 reference

PMCID

2394422

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference

PMCID

2394422